A Phase II Study of the CDK4/6 Inhibitor Abemaciclib in Patients With Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2017
Price : $35 *
At a glance
- Drugs Abemaciclib (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 30 Nov 2017 Status changed from not yet recruiting to recruiting.
- 02 Nov 2017 Planned initiation date changed from 31 Oct 2017 to 15 Nov 2017.